A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of Nexagon® in subjects with Persistent Epithelial Defects (PED) originally caused by chemical burns.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Persistent Epithelial Defect

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Persistent cornea defect Nexagon Coda

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nexagon®

Intervention Type DRUG

Nexagon® vehicle

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects aged 18 years and over.
2. Subjects who are able to attend all follow-up visits and who are able to comply with all study procedures.
3. Subjects who are willing and able to give written informed consent to take part in the study.
4. At the Day -7 visit subjects must have a corneal epithelial defect that has persisted for between 7 days and 14 days, which has a minimum diameter of 2 mm along the greatest axis, and which has not shown improvement despite conventional treatment such as tear supplements and bandage contact lenses.
5. The original defect to the cornea must have been caused by either alkaline or acidic agents.

Exclusion Criteria

1. Use of concomitant ocular medications in the screening period that are not specified in standardized PED treatment regime
2. Likely to require the use of concomitant ocular medications that are not specified in the standardized PED treatment regime during the study follow-up period
3. Decrease or increase in the PED by more than 30% during the screening period.
4. Have an active lid or ocular infectious process of any sort
5. Subjects with corneal perforation or impending corneal perforation
6. The circumference affected by limbal blood vessel ischemia is greater than 75% of the circumference
7. Subjects with severe lid abnormalities contributory to the persistence of the PED such as inability to close the lids.
8. Subjects with bilateral PED, if the smaller PED has a longest diameter of \> 2 mm.
9. Female subjects who are pregnant or breastfeeding. F
10. Subjects who have a history of AIDS or HIV.
11. Subjects with any other condition which, in the Investigator's opinion, would exclude the subject from participating.
12. Treatment with systemic corticosteroids (equivalent to \> 10 mg/day of prednisone) or immunosuppressive or chemotherapeutic agents within 7 days prior to Day 0, or likely to receive one of these therapies during study participation
13. Subjects who have participated in a clinical trial within 30 days prior to Day 0.
14. Diabetics with an HbA1c greater than 6.5%.
15. Diabetics who are currently prescribed more than one oral medication for their diabetes.
16. Subjects who have more than one distinct PED in the study eye.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NEX-PED-001

Identifier Type: -

Identifier Source: org_study_id